Skip to main content

Advertisement

SpringerLink
Log in

Vascular Inflammation Imaging in Psoriasis

  • Cardiac Nuclear Imaging (A Cuocolo and M Petretta, Section Editors)
  • Published:
Current Cardiovascular Imaging Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Psoriasis is a common, chronic inflammatory skin disease driven by immune dysregulation involving helper T cell 17 pathways. Psoriasis is associated with systemic inflammation, which increases the risk of joint disease (psoriatic arthritis), subclinical cardiovascular disease, and major adverse cardiovascular events, especially in young patients with severe skin disease. Furthermore, vascular inflammation by 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) provides a valuable tool with utility in predicting future cardiovascular events. As such, psoriasis provides a clinical human model to characterize the vascular disease by non-invasive imaging techniques such as vascular inflammation by FDG PET/CT.

Recent Findings

FDG PET/CT has garnered considerable interest in multiple completed and ongoing cardiovascular and psoriasis trials. Indeed, recent studies have shown that psoriasis is associated with increased vascular inflammation. Furthermore, a dose-response was demonstrated between severity of skin disease and severity of vascular inflammation in psoriasis. Additionally, observational studies have reported that treatment of psoriasis decreases vascular inflammation with several randomized trials still ongoing. Emerging data from a single report demonstrated that use of FDG PET/MRI may provide soft tissue localization of the FDG tracer in the aorta and the carotids but larger studies are underway.

Summary

This review outlines the initial use, development, and current utility of FDG PET/CT in psoriasis covering cross-sectional and longitudinal studies that examined the relationship between psoriasis, severity of skin disease, presence of joint disease, treatment of skin disease, and emerging techniques to identify vascular inflammation as a marker of cardiovascular risk in psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6. doi:10.1016/j.jaad.2013.11.013.

    Article  PubMed  Google Scholar 

  2. Golden JB, Groft SG, Squeri MV, Debanne SM, Ward NL, McCormick TS, et al. Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation. J Immunol. 2015;195(5):2006–18. doi:10.4049/jimmunol.1402307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–83. doi:10.1038/jid.2009.399.

    Article  CAS  PubMed  Google Scholar 

  4. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutrition Diabetes. 2012;2:e54. doi:10.1038/nutd.2012.26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatology. 2013;149(1):84–91. doi:10.1001/2013.jamadermatol.406.

    Article  PubMed  Google Scholar 

  6. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218–21. doi:10.1016/j.atherosclerosis.2012.06.068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Boehncke WH, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38(3):567–71. doi:10.3899/jrheum.101124.

    Article  PubMed  Google Scholar 

  8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41. doi:10.1001/jama.296.14.1735.

    Article  CAS  PubMed  Google Scholar 

  9. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–6. doi:10.1093/eurheartj/ehp567.

    Article  PubMed  Google Scholar 

  10. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775. doi:10.1016/j.amjmed.2011.03.028. e1-6.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mehta NN, Krishnamoorthy P, Yu Y, Khan O, Raper A, Van Voorhees A, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–8. doi:10.1016/j.jaad.2012.05.016.

    Article  PubMed  PubMed Central  Google Scholar 

  12. • Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging. 2013;6(12):1250–9. doi:10.1016/j.jcmg.2013.08.006. This was the first study to exhibit value for vascular inflammation assessed by FDG PET/CT in future cardiovascular risk prediction. Furthermore, this study also demonstrated an important finding of an inverse association between the degree of vascular inflammation and the duration to the first cardiovascular event.

    Article  PubMed  Google Scholar 

  13. Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging. 2012;5(1):69–77. doi:10.1161/CIRCIMAGING.110.959478.

    Article  PubMed  Google Scholar 

  14. Tawakol A, Lo J, Zanni MV, Marmarelis E, Ihenachor EJ, MacNabb M, et al. Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients. J Acquir Immune Defic Syndr. 2014;66(2):164–71. doi:10.1097/QAI.0000000000000138.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Mehta N. PET assessment of left main coronary arterial inflammation with coronary CT angiography validation before and after statin therapy: more promise for FDG vascular uptake? Circ Cardiovasc Imaging. 2016;9.

  16. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48(9):1825–31. doi:10.1016/j.jacc.2006.03.069.

    Article  CAS  PubMed  Google Scholar 

  17. • Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–17. doi:10.1016/j.jacc.2013.04.066. An important study in the field of vascular inflammation imaging as this double blind, multi-center trial showed that vascular inflammation by FDG PET/CT was subject to variation following statin therapy. Moreover, this study also established a dose-response association between the intensity of statin and reduction in arterial inflammation.

    Article  CAS  PubMed  Google Scholar 

  18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. doi:10.1056/NEJMra043430.

    Article  CAS  PubMed  Google Scholar 

  19. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004–13. doi:10.1056/NEJMra1216063.

    Article  CAS  PubMed  Google Scholar 

  20. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38. doi:10.1016/j.jacc.2009.09.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12. doi:10.1038/ni.2001.

    Article  CAS  PubMed  Google Scholar 

  22. Nahrendorf M, Swirski FK. Immunology. Neutrophil-macrophage communication in inflammation and atherosclerosis. Science. 2015;349(6245):237–8. doi:10.1126/science.aac7801.

    Article  CAS  PubMed  Google Scholar 

  23. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med. 2008;263(5):517–27. doi:10.1111/j.1365-2796.2008.01965.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252(4):283–94.

    Article  CAS  PubMed  Google Scholar 

  25. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161(1):1–7. doi:10.1111/j.1365-2133.2009.09281.x.

    Article  CAS  PubMed  Google Scholar 

  26. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–96. doi:10.1038/jid.2010.103.

    Article  CAS  PubMed  Google Scholar 

  27. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385–422. doi:10.1146/annurev-pathol-011811-132448.

    Article  CAS  PubMed  Google Scholar 

  28. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19(1):5–21. doi:10.1080/09546630701364768.

    Article  PubMed  Google Scholar 

  29. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–34. doi:10.1016/j.clindermatol.2007.08.006.

    Article  PubMed  Google Scholar 

  30. Sundarrajan S, Arumugam M. Comorbidities of psoriasis—exploring the links by network approach. PLoS One. 2016;11(3):e0149175. doi:10.1371/journal.pone.0149175.

    Article  PubMed  PubMed Central  Google Scholar 

  31. •• Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–9. doi:10.1001/archdermatol.2011.119. This was the first study to demonstrate the ability of FDG PET/CT to detect whole-body inflammation. Furthermore, this study showed that psoriasis patients had increased vascular inflammation compared to controls beyond traditional cardiovascular risk factors.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. •• Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arteriosclerosis, thrombosis, and vascular biology. 2015. doi:10.1161/ATVBAHA.115.306460. Another study of importance in the field of vascular inflammation imaging in psoriasis as it revealed a direct association between skin disease severity and the severity of vascular inflammation. Additionally, demonstrating an increased neutrophil activation as well as a direct association between neutrophil marker and both vascular inflammation and psoriasis severity, this study suggested neutrophils to be one of the important links in the shared mechanistic pathways between psoriasis and atherosclerosis.

  33. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411–8. doi:10.1038/jid.2009.112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24. doi:10.1016/j.jacc.2006.05.076.

    Article  PubMed  Google Scholar 

  35. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29(8):1625–30.

    Article  CAS  PubMed  Google Scholar 

  36. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49(6):871–8. doi:10.2967/jnumed.107.050294.

    Article  PubMed  Google Scholar 

  37. Basu S, Zhuang H, Alavi A. Imaging of lower extremity artery atherosclerosis in diabetic foot: FDG-PET imaging and histopathological correlates. Clin Nucl Med. 2007;32(7):567–8. doi:10.1097/RLU.0b013e3180646ac0.

    Article  PubMed  Google Scholar 

  38. Bural GG, Torigian DA, Chamroonrat W, Alkhawaldeh K, Houseni M, El-Haddad G, et al. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept. Nucl Med Biol. 2006;33(8):1037–43. doi:10.1016/j.nucmedbio.2006.08.005.

    Article  CAS  PubMed  Google Scholar 

  39. Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49(14):1533–9. doi:10.1016/j.jacc.2006.11.046.

    Article  CAS  PubMed  Google Scholar 

  40. Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6(5):747–54. doi:10.1161/CIRCIMAGING.113.000382.

    Article  PubMed  Google Scholar 

  41. Lee SJ, On YK, Lee EJ, Choi JY, Kim BT, Lee KH. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008;49(8):1277–82. doi:10.2967/jnumed.108.052233.

    Article  CAS  PubMed  Google Scholar 

  42. Ridker PM. Psoriasis, inflammation, and vascular risk: a problem more than skin deep? Eur Heart J. 2010;31(8):902–4. doi:10.1093/eurheartj/ehq042.

    Article  PubMed  Google Scholar 

  43. Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;63:e3777. doi:10.3791/3777.

    Google Scholar 

  44. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26(13):2155–61. doi:10.1200/JCO.2007.14.5631.

    Article  PubMed  Google Scholar 

  45. Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26(4):314–9.

    Article  CAS  PubMed  Google Scholar 

  46. Beckers C, Ribbens C, Andre B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med. 2004;45(6):956–64.

    CAS  PubMed  Google Scholar 

  47. Curiel R, Akin EA, Beaulieu G, DePalma L, Hashefi M. PET/CT imaging in systemic lupus erythematosus. Ann N Y Acad Sci. 2011;1228:71–80. doi:10.1111/j.1749-6632.2011.06076.x.

    Article  PubMed  Google Scholar 

  48. Rose S, Sheth NH, Baker JF, Ogdie A, Raper A, Saboury B, et al. A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. American J Cardiovasc Dis. 2013;3(4):273–8.

    Google Scholar 

  49. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50(9):892–6. doi:10.1016/j.jacc.2007.05.024.

    Article  PubMed  Google Scholar 

  50. Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55(23):2527–35. doi:10.1016/j.jacc.2009.12.061.

    Article  PubMed  Google Scholar 

  51. Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T. Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging. 2003;30(2):267–73. doi:10.1007/s00259-002-1018-8.

    Article  CAS  PubMed  Google Scholar 

  52. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11.

    Article  CAS  PubMed  Google Scholar 

  53. Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35(3):562–9. doi:10.1007/s00259-007-0528-9.

    Article  PubMed  Google Scholar 

  54. Golden JB, Wang Y, Fritz Y, Diaconu D, Zhang X, Debanne SM, et al. Chronic, not acute, skin-specific inflammation promotes thrombosis in psoriasis murine models. J Transl Med. 2015;13:382. doi:10.1186/s12967-015-0738-z.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wang Y, Gao H, Loyd CM, Fu W, Diaconu D, Liu S, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012;132(8):2067–75. doi:10.1038/jid.2012.112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Youn SW, Kang SY, Kim SA, Park GY, Lee WW. Subclinical systemic and vascular inflammation detected by (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J Dermatol. 2015;42(6):559–66. doi:10.1111/1346-8138.12859.

    Article  PubMed  Google Scholar 

  57. Aberra TM, Joshi AA, Lerman JB, Rodante JA, Dahiya AK, Teague HL, et al. Self-reported depression in psoriasis is associated with subclinical vascular diseases. Atherosclerosis. 2016;251:219–25. doi:10.1016/j.atherosclerosis.2016.05.043.

    Article  CAS  PubMed  Google Scholar 

  58. El Harchaoui K, Arsenault BJ, Franssen R, Despres JP, Hovingh GK, Stroes ES, et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009;150(2):84–93.

    Article  PubMed  Google Scholar 

  59. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff Jr DC, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192(1):211–7. doi:10.1016/j.atherosclerosis.2006.05.007.

    Article  CAS  PubMed  Google Scholar 

  60. Yu Y, Sheth N, Krishnamoorthy P, Saboury B, Raper A, Baer A, et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. American J Cardiovas Disease. 2012;2(4):285–92.

    CAS  Google Scholar 

  61. Rose S, Dave J, Millo C, Naik HB, Siegel EL, Mehta NN. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Res Ther. 2014;16(4):R161. doi:10.1186/ar4676.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35(6):1544–50. doi:10.1161/ATVBAHA.115.305635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, et al. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2016;452:10–7. doi:10.1016/j.cca.2015.11.001.

    Article  CAS  PubMed  Google Scholar 

  64. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3(5):e001221. doi:10.1161/JAHA.114.001221.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs Jr DR. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016. doi:10.1373/clinchem.2016.255828.

    PubMed  Google Scholar 

  66. Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res. 2016. doi:10.1161/CIRCRESAHA.116.309637.

    PubMed  Google Scholar 

  67. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50. doi:10.1016/j.jaad.2008.02.039.

    Article  PubMed  Google Scholar 

  68. •• Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging. 2013;6(1):83–90. doi:10.1161/CIRCIMAGING.112.975730. A single-center, single-blinded, randomized, active-controlled trial that demonstrated an important phenomenon of vascular inflammation reduction in psoriasis patients following treatment with anti-tumor necrosis factor for 15 weeks, while the comparator cohort, who received only topical therapy, did not show a significant reduction in arterial inflammation.

    Article  PubMed  Google Scholar 

  69. Paramanand S, Hamed E, Sharath S, Pal M-H, Gergana M-S, M MH et al. Coronary plaque morphology and the anti-inflammatory impact of atorvastatin: a multi-center FDG-PET/CT study. Circulation Cardiovascular imaging. 2016;9:e004195

  70. Dave J, Ahlman MA, Lockshin BN, Bluemke DA, Mehta NN. Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique. J Am Acad Dermatol. 2014;70(6):1137–8. doi:10.1016/j.jaad.2013.12.043.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009;207(1):139–43. doi:10.1016/j.atherosclerosis.2009.04.023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46(4):608–13.

    CAS  PubMed  Google Scholar 

  73. Rajiah P, Hojjati M, Lu Z, Kosaraju V, Partovi S, O’Donnell JK, et al. Feasibility of carotid artery PET/MRI in psoriasis patients. Am J Nucl Med Mol Imaging. 2016;6(4):223–33.

    PubMed  PubMed Central  Google Scholar 

  74. Blomberg BA, Akers SR, Saboury B, Mehta NN, Cheng G, Torigian DA, et al. Delayed time-point 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation. Nucl Med Commun. 2013;34(9):860–7. doi:10.1097/MNM.0b013e3283637512.

    PubMed  Google Scholar 

  75. Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC, Cullum I, et al. Vascular inflammation imaging with 18F-FDG PET/CT: when to image? Journal of Nuclear Medicine: official publication, Society Nuclear Med. 2009;50(6):854–7. doi:10.2967/jnumed.108.061432.

    Article  Google Scholar 

  76. Mosiewicz J, Pietrzak A, Chodorowska G, Trojnar M, Szepietowski J, Reich K, et al. Rational for statin use in psoriatic patients. Arch Dermatol Res. 2013;305(6):467–72. doi:10.1007/s00403-013-1374-1.

    Article  CAS  PubMed  Google Scholar 

  77. Torres T, Raposo I, Selores M. IL-17 blockade in psoriasis: friend or foe in cardiovascular risk? Am J Clin Dermatol. 2016;17(2):107–12. doi:10.1007/s40257-015-0166-0.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), 10 Center Drive, Clinical Research Center, Room 5-5140, Bethesda, MD, 20892, USA

    Abhishek Chaturvedi, Amit K. Dey, Aditya A. Joshi & Nehal N. Mehta

Authors
  1. Abhishek Chaturvedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit K. Dey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aditya A. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nehal N. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nehal N. Mehta.

Ethics declarations

Conflict of Interests

Abhishek Chaturvedi, Amit K Dey, Aditya A Joshi, and Nehal N Mehta declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and were in compliance with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

This article is part of the Topical Collection on Cardiac Nuclear Imaging

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chaturvedi, A., Dey, A.K., Joshi, A.A. et al. Vascular Inflammation Imaging in Psoriasis. Curr Cardiovasc Imaging Rep 10, 4 (2017). https://doi.org/10.1007/s12410-017-9401-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12410-017-9401-9

Keywords

Search

Navigation